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Abstract
Immunotherapy (eg interferon a) in combination with tyrosine kinase inhibitors is currently in clinical trials for treatment of
chronic myeloid leukemia (CML). Cancer patients commonly have problems with so called immune escape mechanisms that
may hamper immunotherapy. Hence, to study the function of the immune system in CML is of interest. In the present paper
we have identified immune escape mechanisms in CML with focus on those that directly hamper T cells since these cells are
important to control tumor progression. CML patient samples were investigated for the presence of myeloid-derived
suppressor cells (MDSCs), expression of programmed death receptor ligand 1/programmed death receptor 1 (PD-L1/PD-1),
arginase 1 and soluble CD25. MDSC levels were increased in samples from Sokal high risk patients (p,0,05) and the cells
were present on both CD34 negative and CD34 positive cell populations. Furthermore, expression of the MDSC-associated
molecule arginase 1, known to inhibit T cells, was increased in the patients (p = 0,0079). Myeloid cells upregulated PD-L1
(p,0,05) and the receptor PD-1 was present on T cells. However, PD-L1 blockade did not increase T cell proliferation but
upregulated IL-2 secretion. Finally, soluble CD25 was increased in high risk patients (p,0,0001). In conclusion T cells in CML
patients may be under the control of different immune escape mechanisms that could hamper the use of immunotherapy
in these patients. These escape mechanisms should be monitored in trials to understand their importance and how to
overcome the immune suppression.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative
disorder characterized by the Philadelphia chromosome (Ph) [1].
Sokal score predicts the prognosis and divides CML patients into a
low (LR), intermediate (IR) or high risk (HR) group [2]. Regardless
of Sokal score the standard treatment for CML is tyrosine kinase
inhibitors (TKIs). TKIs have profoundly changed the course of the
disease with an overall survival of 88 percent and with 63 percent
of patients still having optimal response after six years of treatment
with the TKI imatinib [3]. So far, the only proven cure for CML is
allogeneic stem cell transplantation where the graft-versus-
leukemia effect is considered to be of central importance implying
immunological mechanisms in the disease control [4,5]. Lately
however, a study with patients discontinuing imatinib has shown
that 41 percent of the patients stopping treatment in complete
molecular response (CMR) remained in CMR at 12 months
follow-up implicating that also imatinib may cure a subpopulation
of patients [6]. With the aim of increasing cure rates and make it
possible for patients to discontinue treatment, TKI therapies are
currently evaluated in combination with immune modulators in
studies that have shown promising results [7,8,9,10]. Because of
the interest of immune modulators in CML a better understanding
of the underlying cancer-associated immune escape mechanisms in
CML is warranted.
Cancer patients are known to have a suppressed anti-tumor
response that complicates the development and use of immuno-
therapy. Myeloid-derived suppressor cells (MDSCs) are a hetero-
geneous cell population of myeloid cells that is known to increase
in many cancers [11] and has been shown to be more suppressive
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in cancer patients than in healthy control subjects (HCs)
[12,13,14]. MDSCs have the ability to inhibit T cell responses
by various mechanisms such as secretion of reactive oxygen species
[15] as well as up-regulation of arginase 1 (Arg1) [16]. The
increased expression of Arg1 leads to L-arginine starvation which
inhibits the immune response by T cell cycle arrest [17]. Since the
tumor cells in CML are immature and of myeloid origin their role
as potential MDSCs are of interest to investigate.
Tumor cells can suppress immunity by direct contact with
immune cells or by secreting immune inhibitory molecules [18].
For example, tumor cells can express programmed death receptor
ligand 1 (PD-L1, CD274, B7-H1), a member of the B7-family of
co-stimulatory molecules, that acts as a co-inhibitory molecule for
T cells by binding the programmed death receptor 1 (PD-1)
upregulated on activated T cells [19]. The expression of PD-L1
and PD-1 in cancer patients has been suggested to lead to disease
progression due to T cell exhaustion [20]. In CML, Mumprecht et
al demonstrated higher PD-1 expression on CD8 T cells compared
to CD8 T cells from healthy control subjects. Further, in a mouse
model of CML they found PD-L1 expression on leukemic cells and
that PD-L1 blockade enhanced survival of CML mice in blast
crisis [20]. A secreted molecule, the soluble form of the IL-2
receptor a-chain, soluble CD25 (sCD25) may be an immune
inhibitor in hematological malignancies [21]. Originally, elevated
levels of sCD25 was associated with lymphocyte activation [22].
However, in hematological malignancies sCD25 is thought to be
released from tumor cells and it has been correlated to tumor
burden in the patients [23]. Moreover, we have previously shown
that sCD25 was released from T regulatory cells in samples from
patients with B cell lymphoma [21].
In the present study, newly diagnosed HR and LR CML
patients were investigated for the presence and nature of immune
escape mechanisms including MDSCs, Arg1, PD-L1/PD-1 and
sCD25 in an attempt to map the immune status of CML patients.
Design and Methods
Patient samples, samples from control subjects, chronic
myeloid leukemia cell lines and ethics statement
Cryopreserved leukapheresis samples from newly diagnosed
CML patients (n = 18, patients 1–18 in Table 1) were obtained
from Uppsala University Hospital Biobank. Fresh blood from
newly diagnosed CML patients (n = 19, patients 11 and 19–36 in
Table 1) was obtained from Uppsala University Hospital, section
of Hematology. Since only a few persons per year are diagnosed
with CML in Uppsala, cryopreserved samples were used to get
enough patient material to study. This study was approved by
Uppsala Regional Research Ethics Committee and all patients
gave their written informed consent (DNr: 2009/288, 2005/164).
The cryopreserved leukapheresis samples had been routinely saved
in Uppsala University Hospital Biobank and before samples were
taken from the biobank written informed consent was obtained
from the patients, as approved by the regional ethics review board.
At the time the patients gave their informed consent they had all
past 18 years of age. As controls, buffy coats from gender- and age
matched control subjects (n = 30) were obtained from the blood
bank at Uppsala University Hospital. For plasma separation,
peripheral blood from control subjects (n = 18) was obtained
through the blood bank at Uppsala University Hospital. Blood
plasma from CML patients and control subjects was obtained by
centrifugation of fresh heparinized blood. Peripheral blood
mononuclear cells (PBMCs) from healthy control subjects were
separated from buffy coats by ficoll separation (GE Healthcare,
Uppsala, Sweden) and cryopreserved in RPMI-1640 supplement-
ed with 40% fetal bovine serum (FBS) and 10% dimethyl sulfoxid
(DMSO) (Apoteket AB, Uppsala, Sweden). Red blood cells in
buffy coats and fresh CML patient blood were lysed by two times
five minutes incubation with red blood cell lysis buffer containing
155 mM NH4Cl, 10 mM KHCO3 and 0,1 mM EDTA at a pH of
7,4. The white blood cells from buffy coats were cryopreserved as
indicated above and the white blood cells from CML patients were
cryopreserved in FBS supplemented with 10% DMSO. For
fluorescent in situ hybridization (FISH) five fresh CML patients
were obtained from Helsinki University central hospital. The
CML cell lines K562, CML-T1 and BV-173 (K562 obtained from
ATCCManassas, VA, USA, CML-T1 and BV-173 obtained from
Deutsche Sammlung von Mikroorganismen und Zellen, Braunsch-
weig, Germany), all originally from CML patients in blast crisis,
were cultured in RPMI-1640 media supplemented with 10% FBS
and 1% penicillin/streptomycin (PEST). All cell culture reagents
were from Invitrogen (Carlsbad, CA, USA).
CD34 separation and Bcr/Abl fluorescent in situ
hybridization
CD34 positive cells from five CML patients were sorted from
peripheral blood as described in [24]. fluorescent in situ
hybridization (FISH) was run on the samples as described in [24].
Antibodies and staining for flow cytometry
Antibodies used for extracellular staining were a-CD3-FITC
(fluorescein isothiocyanate), a-CD3-APC (allophycocyanin), a-
CD4-FITC, a-CD8-PE (phycoerytrin), a-CD8-FITC, a-CD11b-
PE/Cy5, a-CD14-FITC, a-CD33-PE, a-CD34-APC, a-PD-1-
FITC, a-PD-L1-PE (clone: 29E.1A3), IgG1 k-APC, IgG1 k-
FITC, IgG2b k-PE, IgG2a k-PE/Cy5 all from Biolegend (San
Jose, CA, USA). For blocking in cell culture experiments a-PD-L1
antibody (clone: 29E.2A3, Biolegend) or isotype control (clone:
MPC 11, Biolegend) were used. Stainings for flow cytometry were
made on patient leukapheresis (from patients 1–18 in Table 1) and
control samples. The samples were thawed in PBS and run
through a MACS pre-separation filter (Miltenyi Biotech, Bergisch
Gladbach, Germany) to remove clumps of dead cells. Unspecific
antibody binding was blocked with 1% bovine serum albumin
(BSA) (Sigma Aldrich, St Louis, MO, USA) in PBS and cells were
stained for different surface markers. For staining of MDSCs
(patients 1–9 and 11–18 in Table 1), cells were stained for the
surface markers CD34, CD11b, CD14, and CD33. For detection
of PD-L1 on tumor cells the cells (patients 1–12 and 14–18 in
Table 1) were stained for CD34, CD11b, and PD-L1. The
expression of PD-1 on T cells (patients 1–18 in Table 1) was
analyzed by staining of CD3, CD8, and PD-1. Isotype controls
were used to exclude unspecific binding from the analysis. Cells
were analyzed on LSRII (BD Biosciences, Franklin Lakes, NJ,
USA) and the data were evaluated with Flow Jo (Tree star,
Ashland, OR, USA) and BD FACSDiva (BD Biosciences)
software. At analysis live cells were gated depending on the FSC
and SSC properties of the cells. For gating strategies, see Figures
S2, S3, S4 and S6. Median fluorescence intensity (MFI) of PD-L1
was calculated by subtracting the MFI of the isotype control from
the MFI of the sample. For PD-1 the MFIs of the isotype controls
from both patients and HCs were at the same level, hence MFIs of
the samples were reported without subtraction of isotype MFIs.
RNA isolation and cDNA synthesis
Cryopreserved blood samples from CML-patients (n = 6,
patients 11, 24–27 and 32 in Table 1) and control subjects
(n = 9) where red blood cells had been removed were thawed and
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run through a MACS pre-separation filter (Miltenyi Biotech) to
remove clumps of dead cells. For total RNA isolation, RNeasy
Mini Kit (Qiagen, Hilden, Germany) was used and the isolation
was made according to the manufacturer’s instructions. Also RNA
from CML cell lines K562, BV-173 and CML-T1 was isolated
using the same kit. To remove possible DNA contamination, a
DNase free set (Qiagen) was used as instructed by the manufac-
turer. cDNA was synthesized from up to 0,5 mg RNA with iScript
cDNA synthesis kit according to the manufacturer’s instructions
(BioRad, Hercules, CA, USA).
Arginase 1 real time PCR
Real time PCR was performed on cDNA prepared from CML
cell lines and leukocytes from CML patients (n = 6, patients 11,
24–27 and 32 in Table 1) and control subjects (n = 9) with the
CFX96 Real-Time System (BioRad). Reactions were preformed
with the SYBR Green Supermix (BioRad). Gene specific primers
were used for Arg 1: 59-GTT TCT CAA GCA GAC CAG CC-39
(Fw), 59-GCT CAA GTG CAG CAA AGA GA-39 (Rv), for b-
actin 59-CGA GAA GAT GAC CCA GAT CAT G-39 (Fw), 59-
ACA GCC TGG ATA GCA ACG TAC A-39 (Rv). The protocol
Table 1. Patient characteristics.
Patient ID Age1 Sex
Sokal risk
group Eutos score
Spleen size
(cm)2 WBC (109/L)
Platelets
6109/L
PB blasts
(%)
PB basophils
(%)
1 31 F High Low 5 172 365 8 14
2 59 M High Low 10 276 586 8 4
3 37 M High Low 14 180 247 7 2
4 49 F High Low 16 555 588 2 4
5 65 M High Low 10 210 285 3 3
6 53 F High Low 15 322 276 4 1
7 40 M High Low 4 205 824 12 12
8 64 F High Low 0 144 259 5 6
9 37 M High Low 15 219 425 4 5
10 18 M High Low 21 268 488 8 1
11 29 M High Low 20 340 304 6 10
12 66 M Low Low 0 90 205 0 4
13 22 M Low Low 3 220 332 2 2
14 39 M Low Low 2 141 285 1 3
15 50 M Low Low 0 25 406 0 2
16 17 F Low Low 2 268 362 0 4
17 18 M Low - 2 128 208 - -
18 35 M Low - 0 126 264 - -
19 49 F High Low 0 147 1322 1,5 3
20 53 M High Low 0 14 1217 2 8
21 77 F High High 0 25 2674 0 13
22 45 F Low Low 0 25 462 0,5 4,5
23 24 F Low Low 0 45 361 0 6
24 55 M Low Low 0 65 462 0,5 2
25 21 M High High 19 221 838 4 7
26 68 M Low Low 0 72 164 0 1,4
27 61 M High High 8 336 1480 7 8,5
28 63 M Low Low 0 106 196 0,5 4,5
29 41 F Low Low 0 9 731 0 1
30 69 M High High 22 237 574 3 4,4
31 43 M High High 19 238 218 4 10
32 39 F High Low 10 274 469 6 5
33 43 F Low High 0 7,8 699 0 18
34 63 F High High 0 17,3 1800 0 28
35 44 F Low Low 0 141 543 1,5 3,4
36 75 M High Low 8 590 230 6,3 3
Abbreviations: M/F, male/female; WBC, white blood cell count; PB, peripheral blood.
1Age at diagnosis.
2Measured in cm below the left costal margin as assessed by palpation.
doi:10.1371/journal.pone.0055818.t001
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for the reaction was one cycle at 95uC for 3 min, and 40 cycles at
95uC for 9 seconds followed by 60uC for 1 min. Amplification
steps were followed by a melting curve. Data were evaluated using
the BioRad CFX Manager Software (BioRad) and Arg1 expres-
sion was normalized to b-actin expression.
T cell proliferation assay with programmed death
receptor ligand 1 blockade – cell lines
50 000 PBMCs from healthy donors were plated in a 96 well
plate and stimulated with 80 IU/ml IL-2 (Proleukein, Novartis,
Basel, Switzerland). Cells from the two cell lines K562 and BV-173
were irradiated at the dosage of 60 Gray (Gy) and 12 Gy
respectively and blocked with 5 mg/ml PD-L1 blocking antibody
(Biolegend), or 5 mg/ml isotype control (Biolegend) before being
added to the PBMCs. Blocked cell lines were then mixed with
PBMCs in a 1:1 ratio and co-cultured for 2 days in RPMI-1640
media supplemented with 10% FBS and 1% PEST. As controls,
cell lines and PBMCs were cultured alone. After 2 days thymidine
3H (PerkinElmer, Waltham, MA, USA) was added and cells were
harvested (Harvester 96H Mach III M, Tomtec, Hamden, CT,
USA) on to a membrane after 6 hour of incubation. Incorporation
of thymidine 3H was measured by the 1450 MicrobetaH TriLux
from PerkinElmer. Proliferation of PBMCs was evaluated by
subtracting the amount of thymidine 3H incorporated in the cell
lines cultured alone from the incorporation of thymidine 3H in the
PBMC/cell line co-cultures.
T cell proliferation assay with programmed death
receptor ligand 1 blockade and in vitro T cell stimulation
– patient samples
Cryopreserved CML samples from peripheral blood (n= 11,
patient 11, 19–27 and 32 in Table 1) and control samples from
buffy coats (n = 10) were thawed and cultured in RPMI-1640
media supplemented with 10% FBS and 1% PEST over night.
PBMCs from one healthy donor were thawed and cultured over
night. The next day CD3 positive MACS microbead selection was
run on patient and control subject samples, according to the
manufacturer’s instructions. Fc-recptor block was added to the
cells before the addition of microbeads. All reagents were from
Miltenyi Biotech. After selection, CD3 negative cells were cultured
in RPMI-1640 media supplemented with 10% FBS and 1% PEST
for 2–3 hours before being used in proliferation assays. After 2–
3 hours CD3 negative cells from patients and control subjects were
divided into two tubes per sample, pelleted and incubated with
3 mg/ml PD-L1 blocking antibody or isotype control, respectively,
for 30 minutes. Blocked cells were mixed with responder PBMCs
from a control subject in a 1:1 ratio. Cells were pelleted and
resuspended in RPMI 1640 media supplemented with 10% FBS
and 1% PEST and plated in 96-well plates. PD-L1 blocking
antibody or isotype control (3 mg/ml), respectively, was added to
the wells together with 100 IU/ml IL-2 (Novartis). For in vitro
stimulation of T cells CD3 cells were cultured in 96-well plates
with or without the addition of 1,7 mg/ml anti CD3-antibody
(clone OKT-3, BioLegend) and 100 IU/ml IL-2. After 2 days of
culture, proliferation in co-cultures and in vitro stimulated CD3
cells was evaluated using Click it proliferation kit (Invitrogen)
according to the manufacturer’s instruction. Briefly, 5 mM 5-
ethynyl-29-deoxyuridine (EdU) was added to proliferation assays
and cells were cultured over night to incorporate EdU into DNA
of proliferating cells. Cells were washed and to exclude dead cells
from analysis, the LIVE/DEAD staining kit (Invitrogen) was used
according to the manufacturer’s instruction. Cells were blocked in
1% BSA where after T cells were stained with a cocktail of a-CD3-
FITC, a-CD4-FITC and a-CD8-FITC. EdU incorporation was
detected with Click it detection reagent mix. The reaction was
performed in smaller volume than stated in protocol from
manufacturer and the components of the reaction mixture were
scaled down accordingly. Samples were analyzed on LSRII (BD
Bioscience) and data were analyzed with Flow Jo software (Tree
Star). Supernatants from co-cultures (patients 11, 19–27 and 32
from Table 1) were taken for IL-2 ELISA after overnight
incubation with EdU and stored in 280u until analysis.
Arginase 1, soluble CD25 and IL-2 ELISA
Arg 1 protein levels in plasma from CML patients (n = 10,
patients 11, 19–20, 25, 29 and 32–36 in Table 1) were assessed
using an ELISA from Hycult Biotech (Plymouth Meeting, PA,
USA). The ELISA was performed according to the manufacturer’s
instructions. Arg 1 can be released from lysed erythrocytes, hence
to avoid false positive values hemolysed plasma samples were
excluded from the analysis. The level of sCD25 in plasma from
CML patients (n = 14, patients 11 and 20–32 in Table 1) and
control subjects (n = 18, control subjects plasma samples were a
subpopulation derived from a cohort of healthy donors previously
published in [21]) was measured using a sCD25 ELISA from
Diaclone (Besancon Cedex, France) according to the manufactur-
er’s instructions. To determine the IL-2 concentration in
supernatants from proliferation experiments, an ELISA using IL-
2 Eli-Pair set (Diaclone) was performed.
Statistical analysis
Statistical analyses were made with Prism Software (Graphpad
Software Inc., La Jolla, CA, USA). To assess statistical significance
of difference between more than two groups the Kruskal Wallis
test was used. When statistical significant difference between
groups was found, Dunn’s post test was applied.
Results
Patient characteristics
All CML patients were newly diagnosed and in chronic phase.
The mean age of the patients was 46 years ranging from 17 to 77
years. Twenty one patients were Sokal high risk (HR) and 15 were
Sokal low risk (LR) (Table 1). Eight patients (patient 3, 5, 21, 22,
25, 28, 31 and 34 in Table 1) had been treated with hydroxyurea
for 1–4 days prior to leukapheresis or blood sampling, patients
were otherwise untreated. After the initiation of this study, a new
scoring system for CML patients on TKI treatment, called the
EUTOS score [25], has come to light. EUTOS score of the
patients can be seen in Table 1, but all analyses compare the Sokal
HR and LR groups.
CD34 positive cells from peripheral blood of chronic
myeloid leukemia patients originates from the leukemic
clone
Peripheral blood from five CML patients was sorted with
magnetic beads and Ph positivity in CD34 positive cells was
measured by FISH. The percentage of FISH positive cells in the
CD34 fraction ranged from 77–98% with a median of 95% (see
Figure S1)
Chronic myeloid leukemia patients have increased
myeloid derived suppressor cell numbers and high
arginase 1 levels
The level of MDSCs, here defined as CD11b+CD142CD33+
cells, was investigated using flow cytometry (for gating strategy, see
Immune Escape in Chronic Myeloid Leukemia
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Figure S2). We found that MDSC levels were similar in the whole
CML patient population (n= 17) compared to control subjects
(n = 21). However, when dividing patients into HR (n= 10) and
LR (n= 7) groups, the HR group had statistically significant higher
MDSC level compared to both LR patients and control subjects
(p,0,05 and p,0,01 respectively, Figure 1A). Since MDSCs and
CML tumor cells share some features we hypothesize that the
tumor cells themselves may be MDSCs. At the time of the study
there were no specific markers for CML tumor cells available for
flow cytometry analysis. However, since we show that 95% of
CD34 positive cells in peripheral blood were Ph positive (Figure
S1) CD34 was used as a marker for CML tumor cells. When
investigating CD34 expression on CML patient MDSCs we found
that a median of 35% of MDSCs expressed CD34 demonstrating
that some tumor cells may be accounted for as MDSCs (Figure 1B).
Investigating CML cell lines K562 and BV-173 for MDSC
markers, we found that in both cell lines about half of the cells
expressed the MDSC markers (data not shown). The expression of
the MDSC-associated molecule Arg1 was assessed in leukocytes
from CML patients (HR n=4, LR n= 2) and control subjects
(n = 9) as well as in CML cell lines with real time PCR. The
relative expression of Arg1 in leukocytes was higher in HR patients
compared to control subjects (p,0,05, Figure 1C) Statistical
difference between control subjects and LR patients could not be
determined because of too few LR samples. Arg1 mRNA levels
were also determined in four more patients that were in
accelerated phase or Sokal intermediate risk. Also in these patients
Arg1 mRNA levels were higher than in HCs (data not shown).
Arg1 protein levels in CML patient plasma (LR n=3, HR n=7)
were assessed with ELISA. In all patients the Arg1 plasma levels,
ranging from 35–316 ng/ml (Figure 1D), were higher than
reported normal median levels ( 9.5664.03 ng/mL to 21.969.2
[26,27,28]).The CML cell line K562, but not the cell lines BV-173
or CML-T1, expressed Arg1 mRNA (Figure 1E).
Chronic myeloid leukemia cells express high levels of the
co-inhibitory molecule programmed death receptor
ligand 1
Myeloid cells (CD11b+) in CML patients and control subjects
were analyzed for the co-inhibitory molecule PD-L1 expression by
flow cytometry (for gating, see Figure S3). A median of 48% of
CD11b cells from CML patients (n = 17) expressed PD-L1, this
was significant different from the expression in control subjects
(n = 21) where 23% of CD11b cells expressed PD-L1 (p,0,05).
There was no difference between LR or HR groups concerning
the percentage PD-L1 expressing CD11b cells (Figure 2A). The
expression level of PD-L1 molecule on single CD11b cells, assessed
as median fluorescence intensity (MFI) was not significantly higher
in patients compared to control subjects (Figure 2B). In most
patients however, there was a subgroup of CD11b cells expressing
high levels of PD-L1, this subgroup was not seen as frequently in
control subject cells (Figure 2C and Figure S3). HR patients had a
significantly increased level of PD-L1 expressing CD34 cells
compared to control subjects (p,0,05) while LR patients
resembled the control subjects (Figure 2D). However, most PD-
L1 positive cells were found in the CD11b+CD342 population in
HR patients. The same trend was seen in LR patients but the
difference did not reach significance (data not shown). Overall,
PD-L1 positive peripheral leukocytes were more frequent in CML
patients than in control subjects (data not shown).
T cells from chronic myeloid leukemia patients express
high levels of programmed death receptor 1
To investigate the relevance of PD-L1 expression on myeloid
cells, the expression of its receptor PD-1 was analyzed on patients’
and control subjects’ T cells (for gating strategy, see Figure S4).
The HR patients (n = 11) had a significant increase of PD-1
positive CD3+CD8+ cytotoxic T cells compared to control
subjects (n = 21) (p,0,05, Figure 3A). Moreover, the PD-1
expression on the cell surface of CD8 cells was higher in both
LR and HR patients compared to control subjects (p,0,05 and
p,0,05 respectively, Figure 3B and Figure S4). There was a
slightly higher level of CD8 positive and a slightly lower level of
CD8 negative T cells in HR patients compared to healthy controls
(Figure S5). T helper cells (analyzed as CD3+CD82 cells)
expressing PD-1 seemed to be increased in HR patients (n = 11)
compared to control subjects (n = 21) but the difference did not
reach significance (Figure 3C). However, there was an increase in
PD-1 MFI on CD8 negative cells both in LR and HR patients
compared to controls (p,0,05 and p,0,05 respectively,
Figure 3D).
The effect of programmed death receptor ligand 1
blockade
CML cell lines K562, CML-T1 and BV-173 were all positive
for PD-L1 expression as analyzed flow cytometry (Figure 4A).
K562 and BV-173 were used in a proliferation assay to investigate
if PD-L1 blockade would increase the proliferative response of
healthy donor PBMCs. All donors reacted to the tumor cell lines
by proliferation. However, the effect of PD-L1 blockade was
modest implicating that PD-L1-induced tolerance is not of great
importance in this setting (Figure 4B). PD-L1 expression is also
seen on CML patient cells as seen in Figure 2A. To investigate if
the PD-L1 expression on CML patient cells can inhibit
proliferation of healthy T cells and if this inhibition could be
released by PD-L1 blockade, PBMCs from an individual control
subject (responder cells) were stimulated with IL-2 and co-cultured
with CD3 negative CML cells (HR n=7, LR n= 4) or cells from
control subjects (n = 15) (inhibitor cells) (for gating strategy, see
Figure S6). CD3 negative cells were chosen as inhibitor cells to
include as many PD-L1 expressing cells as possible. There was no
significant difference in T cell proliferation in cultures with CML
cells from HR or LR patients (Figure 4C). Blocking PD-L1 on the
inhibitor cells by adding a-PD-L1 antibodies did not affect T cell
proliferation (Figure 4C). To assess T cell function and the
inhibition thereof in another manner, the IL-2 concentration in
the culture supernatants was evaluated. There was a slight,
increased in IL-2 concentration after PD-L1 blockade in samples
from most control subjects and LR patients while a majority of
samples from HR patients had a slight IL-2 concentration
decrease after blockade (Figure 4D). This proliferation experiment
was also run with cells from another four CML patients that were
either Sokal intermediate risk patients or accelerated phase patient
similar results in proliferation and IL-2 secretion was seen for these
patients (data not shown).
T cell proliferation after in vitro stimulation is not altered
in CML
Proliferative response from sorted T cells from CML patients
and control subjects was assessed after in vitro stimulation (HC
n=10, HR n=3, LR n= 3). There was no difference in
proliferation of stimulated cells from CML patients and healthy
controls (Figure S7).
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Soluble CD25 plasma levels are increased in chronic
myeloid leukemia patients
Another mechanism of T cell suppression is the deprivation of
IL-2 and/or other important factors for T cell growth. We have
previously shown that sCD25 can suppress T cell proliferation
likely by sequestering IL-2. Therefore we sought to investigate the
presence of sCD25 in CML patients. The level of sCD25 in blood
plasma from CML patients (n = 14) and control subjects (n = 18)
was studied using ELISA. The level was significantly higher in HR
patients compared to the level in control subjects (p,0,0001
Figure 5).
Discussion
The impact of the immune system and the importance of
immune escape mechanisms in cancer development have been
shown for various cancer forms including hematologic malignan-
Figure 1. Myeloid derived suppressor cell (MDSC) and arginase 1 (Arg1) levels. (A) Levels of MDSCs (CD11b+CD142CD33+) in different
CML patient risk groups (high risk (HR) n = 10, low risk (LR) n = 7) and healthy control subjects (HC, n = 21) as shown by flow cytometry. (B) Levels of
MDSCs expressing CD34 in CML patient risk groups (HR n= 10, LR n= 7) and HCs (n = 21). (C) Arg1 mRNA expression in HCs (n = 9) and CML patients
(HR n=4, LR n = 2) assessed by real time PCR. Statistically significant differences between groups are indicated by P-values in the figures. (D) Arg1
concentration in CML patient plasma (HR n=7, LR n= 3) measured by ELISA. (E) Arg 1 mRNA expression in CML cell lines. The plot shows mean values
with standard error of the mean.
doi:10.1371/journal.pone.0055818.g001
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cies [29,30]. In this study we have investigated the presence of
different immune escape mechanisms in CML. The impact of the
immune response in hematologic malignancies such as CML is
especially intriguing since the malignant transformations occur in
cells of the immune system. Furthermore in the only proven
curative treatment of CML, allogeneic stem cell transplantation,
the graft versus leukemia effect is thought to be of importance
implicating the importance of immune control in CML. To better
understand the immune status in CML and to compare the
immune status of HR and LR patients, samples from newly
diagnosed patients were investigated for the presence of MDSCs,
Arg-1, PD-L1/PD-1, as well as sCD25, all important regulators of
T cell anti-tumor immunity. Since one of our goals was to
compare HR and LR patients we aimed to investigate the same
amount of LR and HR leukapheresis samples. However, since
fewer LR patients undergo leukapheresis fewer LR samples could
be investigated in our study.
Recruitment of MDSCs is a known immune escape mechanism
exerted by many solid tumors [11,31,32] and the level of
circulating MDSCs have been correlated with disease stage in
breast cancer [33]. MDSCs are characterized as immature
myeloid cells and since CML cells mostly consist of immature
myeloid cells and thus share features with MDSCs, we hypoth-
esized that the tumor cells themselves might be MDSCs.
Supporting this hypothesis are our results showing that two
CML cell lines tested both expressed MDSCs markers. Further-
more, we show that most patients had CD34 cells (mostly tumor
cells) expressing MDSC markers. However, the majority of
MDSCs did not express CD34. In our studies we define MDSCs
as CD11b+CD142CD33+ cells, a phenotype that others have
shown to be suppressive in different cancer forms like renal cell
carcinoma and soft tissue sarcoma [34]. In our cohort of CML
patients we could, in peripheral blood, see an increased level of
MDSCs in HR patients compared to control subjects. In some
patients with solid cancers high levels of MDSCs correlate with a
worse prognosis [29]. Interestingly, in our study HR patients had
higher levels of MDSCs compared to LR patients, hence the
correlation with worse prognosis may be true also for CML, but it
needs to be confirmed in a larger study. We have also shown that
CML cells from peripheral blood have higher expression of Arg1
than cells from healthy control subjects and that our CML cohort
had high Arg1 plasma levels. This is in concordance with results
from other groups showing high levels of Arg1 in cancer patient
plasma or serum [29,35]. Since expression of Arg1 can result in
inhibition of T cells [17] the increased levels of MDSCs and high
expression level of Arg1 in CML patients may promote immune
escape in CML.
Figure 2. Programmed death receptor ligand 1 (PD-L1) expression levels on patient cells. (A) PD-L1 expression on myeloid (CD11b+) cells
from patients (HR n=11, LR n = 6) and HCs (n = 21) as assessed by flow cytometry. (B) Median fluorescence intensity (MFI) of PD-L1 on CD11b cells. (C)
MFI of PD-L1 expression on CD11b cells from a representative healthy control (filled histogram) and CML patient (thick line), the thin line represents
the isotype control. (C) Percent PD-L1 expressing CD34 cells of all live cells in HCs (n = 21), LR (n = 6) and HR (n = 11) patients. Statistically significant
differences between groups are reported as P-values in the figures.
doi:10.1371/journal.pone.0055818.g002
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Next, we investigated the presence of the immune regulatory
molecules PD-1 and PD-L1. PD-L1 is normally expressed on
different immune cells like T cells, B cells, dendritic cells and
macrophages as well as non-immune cells like endothelial cells and
pancreatic islets and functions as an important immune regulatory
mechanism as it inhibits T cells by binding to PD-1 upregulated on
activated T cells [36]. Besides being an important immunoregu-
latory mechanism the PD-1/PD-L1 interaction is also an
important immune escape mechanism in some cancers and
infectious diseases. This is illustrated by the fact that antibodies
blocking the interaction can induce remission in patients with
advance stage solid tumors [37,38,39,40]. Moreover, PD-L1 on
tumor cells and PD-1 expression on tumor-infiltrating cells has
been reported to correlate with advanced stage disease and a
worse prognosis by some investigators [30,41,42] while others
have found no correlation between PD-L1 expression on tumor
cells and the prognosis of the patients [43]. Since CML cells
originate from immune cells it is likely that they can play a part in
modulating the immune responses for example by high expression
of PD-L1. In our study we have shown that CML patients
expressed higher levels of PD-L1 on myeloid cells compared to
control subject cells. In concordance with Mumprecht et al we also
show that the expression of PD-1 was higher on cytotoxic T cells
from CML patients than those from control subjects [20]. In a
CML mouse model these authors showed that blocking the PD-1/
PD-L1 interaction increased the survival of CML mice in blast
crisis indicating that PD-1/PD-L1 interaction might be an
important immune inhibitory mechanism in CML [20]. To
investigate the contribution of PD-1/PD-L1 interaction to
immune regulation in our CML cohort, the proliferation of
healthy T cells in response to CML patient cells and cell lines in
the presence of PD-L1 blocking antibodies was studied. We found
that blocking the PD1/PD-L1 interaction did not increase
proliferation of healthy T cells. These results are in line with
those from Salih showing that PD-L1 blockade did not induce T
cell activation despite high PD-L1 expression on patient cells and
leukemic cell lines co-cultured with the T cells [44]. Taken
together these results implicate that PD-1/PD-L1 interaction may
have different functions in solid tumors and in leukemia.
Furthermore, results from mouse models may not always translate
into the human setting. Moreover, our data are obtained in vitro
and may not correlate to the effect in vivo. It is also important to
consider that our co-culture experiment illustrated the ability of T
cells to proliferate and not the T cell function. PD-L1 interaction
with PD-1 on T cells leads not only to inhibition of proliferation
but also to decreased IL-2 secretion by blocking downstream
pathways of PI-3 kinase and Akt [45]. Therefore, to further
investigate the influence of PD-L1 blockade on T cell function we
Figure 3. Programmed death receptor 1 (PD-1) expression on T cells. (A) The percentage of PD-1 positive cytotoxic T cells (CD3+CD8+) in
HCs (n = 21), LR (n = 7) and HR (n = 11) as determined by flow cytometry. (B) The PD-1 MFI is shown for cytotoxic T cells. (C) The percentage of PD-1
positive T helper cells (CD3+CD82) in HCs (n = 21), LR (n = 7) and HR (n = 11) patients was determined by flow cytometry. (D) The PD-1 MFI for helper
T cells. Statistically significant differences between groups are indicated as P-value in the figure.
doi:10.1371/journal.pone.0055818.g003
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Figure 4. Blocking of programmed death receptor ligand 1 (PD-L1) in co-cultures. (A) PD-L1 expression on the CML cell lines K562, BV-173
and CML-T1 was evaluated by flow cytometry. The thick line represents staining with specific antibody and the filled histograms represent the
staining with isotype control antibody. (B) Proliferative response of healthy donor PBMCs to CML cell lines with or without addition of PD-L1 blocking
antibody. The bars show the proliferative response in different wells after subtraction of proliferation seen when cells lines were cultured alone. The
experiment was repeated twice with four donors. Proliferation was measured by thymidine H3 incorporation on triplicate samples. (C) T cell-depleted
leukocytes from CML patients (HR n=7, LR n = 4)) and HCs (n = 15) were co-cultured with PBMCs from a control subject (responder) with addition of
an irrelevant antibody (iso) or an antibody blocking PD-L1 (aPD-L1). The percentage of proliferating T cells in the co-culture is shown. (D) The
concentration of IL-2 in co-culture supernatants from HCs (n = 15), LR (n = 4) and HR (n = 7) was assessed by ELISA. The increase/decrease in IL-2
concentration for the individual control subjects and CML patients are shown in the figure.
doi:10.1371/journal.pone.0055818.g004
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measured the IL-2 concentration in co-culture supernatants. PD-
L1 blockade increased the concentration of IL-2 in the medium
from most healthy control samples and in LR patients indicating
that the interruption of PD-1/PD-L1 interaction enhanced T cell
function. However, in co-cultures with CML cells from most HR
patients the IL-2 concentration in the medium was decreased after
addition of blocking antibody implicating that the PD-1/PD-L1
interaction may have different function in these patients. Clearly,
the PD-L1/PD-1 pathway in leukemia needs further investigation
before testing PD1/PD-L1 blockade as treatment for CML.
The lack of increased in vitro T cell proliferation after PD-L1
blockade may reflect that there are immune escape mechanisms
other than PD-L1 blocking T cell responses in CML. Moreover, in
in vitro stimulation T cell proliferation assays we saw no inhibition
of CML T cell proliferation compared to T cells from control
subjects which may implicate that T cell suppression does not
occur when T cells are separated from the suppressive tumor cells.
One of these mechanisms could be the increased concentration of
sCD25 that we have detected in CML blood plasma. sCD25 can
act immunosuppressive by binding free IL-2 [46], thereby
inhibiting it to bind to and support T cell activation. We as well
as others have shown that patients with hematological malignan-
cies, such as B cell malignancies and CML, have increased level of
sCD25 in plasma [21,23,47,48]. Several studies have shown that
patients in advanced stages of disease have higher levels of sCD25
in plasma compared to patients in less advance stages and that
sCD25 can be a prognostic factor for patients with lymphoma
[47,49,50,51,52]. In CML, patients in accelerated phase and blast
crisis have higher levels of sCD25 in plasma [47,50]. In the present
paper we show that the level of sCD25 in plasma is higher in HR
patients. Since high levels of sCD25 have been associated with
activated T cells [22] this could indicate many activated T cells in
CML patients, especially in HR patients. However, our other
results presented here do not indicate a high level of T cell
activation, thus, the high level of sCD25 probably originates from
another source. Since HR patients have higher tumor burden and
also higher sCD25 levels compared to LR patients we hypothesize
that the sCD25 might be secreted from the tumor cells. This
hypothesis is in line with results from Motoi et al that show that the
level of sCD25 in plasma is correlated with the amount of blasts
and leukocytes in peripheral blood of CML patients in blast crisis
[48]. Moreover, Hermann et al have shown that leukemic stem
cells from CML patients express CD25 on their surface further
supporting that CD25 may be produced and perhaps released
from CML tumor cells [53].
Taken together, anti-tumor reactive T cells in CML may be
controlled by multiple immune escape strategies including
recruitment of MDSCs, expression of Arg1, PD-L1, PD-1, and
sCD25. Some of these immune escape mechanisms seem to be
more pronounced in some Sokal HR patients, if the high
prognostic score is a consequence of immune escape mechanisms
in the patients or if the high prognostic score (and probably a
higher tumor burden) leads to immune escape mechanisms needs
to be further investigated. Previously it has been shown that CML
patients with a higher tumor burden had lower levels of T cells
directed towards the junction of the Bcr/Abl protein compared to
patients with lower tumor burden [54] implicating that the Bcr/
Abl junction is immunogenic and that a low tumor burden can
stimulate an immune response while high tumor burden on the
other hand may suppress T cells, possibly by membrane bound or
secreted factors. For some of the parameters studied in this paper,
the significant difference seen between HR patients and control
subjects in expression levels is created by a few outliers. These
patients may be of importance to study since they may be patients
that are less susceptible to immunotherapy, these may also be the
patients that relapse after stopping TKI treatment. It has been
shown that HR patients have an increased risk of relapse after
TKI treatment cessation [6]. The presence of immune escape
mechanisms could aggravate the use of immunotherapy such as
IFNa in CML and should therefore be monitored during such
studies. This is especially relevant for upcoming trials combining
IFNa and TKIs since IFNa is added to improve the anti-tumor
response. Furthermore, the effect of TKIs on immune escape
mechanisms in CML needs to be studied since TKIs has been
shown to have effect on other immune cells.
Supporting Information
Figure S1 Level of Ph+ cells. The level of Ph+ cells was
measured by FISH in sorted CD34 cells from peripheral blood
from CML patients.
(TIF)
Figure S2 Stategy for MDSCs gating. The percentage
MDSCs of live cells were calculated as the percentage of cells
inside the ‘‘live’’ gate that were CD11b+CD142CD33+. The
percentage CD34 cells of MDSCs were calculated as the
percentage CD34 positive cells inside the MDSC gate.
(TIF)
Figure S3 Strategy for gating CD11b and CD34 cells
expressing PD-L1. The percentage of PD-L1 positive cells in
the CD11b population was calculated as the percentage of PD-L1
positive cells inside the CD11b gate. PD-L1 MFI histograms were
created from the CD11b gate, isotype control is shown as a thin
line. The percentage of CD34+PD-L1+ of live cells was calculated
as the percentage CD34+PD-L1+ cells in the ‘‘live’’ gate.
(TIF)
Figure S4 Strategy for gating PD-1 positive T cells. The
percentage of PD-1 cells of CD8 cells was calculated as the
percentage of PD-1 positive cells (right upper quadrant) of total
CD8 cells (left and right upper quadrants). The percentage of PD-
1 cells of CD8 negative cells was calculated as the percentage of
PD1 positive cells (right lower quadrant) of total CD8 negative
cells (left and right lower quadrant). PD-1 MFI histograms were
Figure 5. Soluble CD25 concentration. The concentration of
soluble CD25 in blood plasma from CML patients (LR n = 6, HR n= 9)
and HCs (n = 18) was investigated with ELISA. The figure shows soluble
CD25 concentration expressed as pg/ml in blood plasma. Statistically
significant difference between groups is reported as P-value in the
figure.
doi:10.1371/journal.pone.0055818.g005
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created from CD8 cell gate (left and right upper quadrants),
isotype control is shown as a thin line.
(TIF)
Figure S5 T cell levels. Level of CD8 (A) and CD8 negative
(B) cells in LR (n= 7) and HR (n= 12) patients compared to HR
(n= 21). Statistically significant differences between groups,
reported as P-value in the figures were assessed by the non-
parametric Kruskal Wallis test and Dunn’s post test.
(TIF)
Figure S6 Strategy for gating proliferating T cells. The
proliferating cells were calculated as the percentage of cells positive
for the proliferation marker EdU in the CD3 gate.
(TIF)
Figure S7 Proliferation of in vitro stimulated T cells.
The percentage of proliferating T cells after in vitro stimulation of T
cells from HCs (n= 10), LR (n= 3), HR (n= 3) patients.
(TIF)
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